Lareb notes newly reported deaths shortly after vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a total of 15 reports so far regarding deaths shortly after receiving the COVID-19 vaccinations.
New research in GGD test lanes on spread of coronavirus SARS-CoV-2 RIVM is launching a survey-based study this week on risk factors for the coronavirus SARS-CoV-2. The participants in this study are people who get tested for COVID-19 in a GGD test lane.
80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
New variants disrupt plans In the past week, from 27 January to 2 February, 28,628 people in the Netherlands reportedly tested positive for COVID-19, a 20% decrease compared to the week of 20 to 26 January.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Less STI tests in The Netherlands The number of people who were tested for a Sexually Transmitted Infection (STI) at a Dutch STI clinic has dropped for the first time in years.
RIVM and Chinese monitoring center for oceans exploring collaboration Knowledge development in China is valuable for addressing environmental issues in Europe, and vice versa.
Technical files of silicone breast implants show shortcomings For medical devices such as breast implants, manufacturers are obliged to compile a ‘technical file’ based on which market authorization of the product will be decided.
Annual report 2015 RIVM online In our annual report, we look back at compelling RIVM projects and research in 2015.